Biogen Makes Lifecycle Gambit In Next-Gen MS Drug Deal With Alkermes
ALKS 8700 could help Biogen extend its MS franchise beyond Tecfidera. The next-generation fumarate may have better GI tolerability and patent protection into 2033.
You may also be interested in...
Label offers little differentiation from Tecfidera, but head-to-head trial with custom-designed patient-reported outcome could make case for gastrointestinal tolerability advantage.
Immuno-oncology R&D based around an interleukin-2 agonist in early clinical studies has attracted attention to Alkermes, but the CNS disorders specialty company is also concentrating on a new mechanism-of-action antidepressant that is nearing the market, and a new antipsychotic.
Astellas builds on a 2013 collaboration by acquiring Mitobridge. Ardelyx is partnering with Kyowa Hakko Kirin to bring tenapanor to market in Japan. Meanwhile, Depomed, Xoma and Bristol all offload programs before the end of the year.